ScreenerHero

BBOT BridgeBio Oncology Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · bbotx.com
3.440USD-1.71%Mkt Cap: 275.80M $P/E: —

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase maligna…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap275.80M USD
Enterprise Value57.41M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-134.04M USD
Revenue/Share—
Last Price3.440 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees88
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.29
PEG—
EV/EBITDA-0.29
EV/Revenue—
P/S—
P/B0.87
EPS (TTM)-0.07
EPS (Forward)-2.72
52W Range
3.3601% of range14.87
52W High14.87 USD
52W Low3.360 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.61%
ROA-29.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-113.89M USD
CapEx (TTM)606.00K USD
FCF Margin—
FCF Yield-32.63%
Net Debt-223.20M USD
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.01
Current Ratio4.69
Quick Ratio4.38
Book Value/Sh4.03 USD
Cash/Share2.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)24.55 USD
Upside (mean)+613.5%
Target Range15.00 USD – 50.00 USD
15.00+613.5% to mean50.00
# Analysts11
Ownership
Shares Out.80.17M
Float35.81M
Insiders27.13%
Institutions71.01%
Short Interest
Short Ratio6.5d
Short % Float12.60%
Short % Out.4.49%
Shares Short3.60M
Short (prev mo.)5.81M
Technical
SMA 507.270 (-52.7%)
SMA 2009.016 (-61.8%)
Beta0.65
S&P 52W Chg16.45%
Avg Vol (30d)636.51K
Avg Vol (10d)631.04K
Technical Indicators
RSI (14)18.2
MACD-1.1221
MACD Signal-1.1381
MACD Hist.+0.0160
BB Upper7.170 USD
BB Middle4.620 USD
BB Lower2.070 USD
BB Width110.39%
ATR (14)0.3829 USD
Vol Ratio (20d)0.39x